News & Updates

A post hoc analysis of the Semaglutide Treatment Effect in People with Obesity (STEP) clinical trials has shown that the treatment effect and safety profile of semaglutide 2.4 mg, compared with placebo, are consistent across racial and ethnic subgroups.

In the EARLY* trial, a 16-week intervention consisting of a 5:2 intermittent fasting meal replacement (5:2 MR) diet trumps two antidiabetic agents in improving glycaemic control and weight loss, as well as BP, TG, and HDL-C** levels in overweight or obese Chinese individuals with newly diagnosed type 2 diabetes (T2D).

Machine learning models can predict patients with new-onset diabetes who are at greater risk for developing pancreatic cancer, a study has shown.

Tirzepatide appears to yield substantially greater reductions in weight than semaglutide in the real-world treatment of overweight or obesity in adults with or without diabetes, according to a study.

Poor glycaemic control in patients with type 1 (T1D) or type 2 diabetes (T2D) contributes to a faster estimated glomerular filtration rate (eGFR) decline following diabetic kidney disease (DKD) onset, suggests a study. This association is more pronounced among those with severe albuminuria.

Use of rosuvastatin is associated with a significantly lower decline in left ventricular ejection fraction (LVEF) and lower serum levels of cardiotoxicity-associated biomarkers in newly diagnosed HER2-positive breast cancer patients treated with anthracycline-based chemotherapy followed by trastuzumab, according to the results of a prospective, randomized, controlled, parallel study.